Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:non-small_cell_lung_cancer
gptkb:FDA |
| gptkbp:ATCCode |
L01EG04
|
| gptkbp:CASNumber |
2094015-54-3
|
| gptkbp:developedBy |
gptkb:Mirati_Therapeutics
|
| gptkbp:hasMolecularFormula |
C32H35ClFN7O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Adagrasib
|
| gptkbp:indication |
locally advanced or metastatic NSCLC with KRAS G12C mutation
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
KRAS inhibitor
|
| gptkbp:PubChem_CID |
CHEMBL4297597
134587884 DB16382 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue liver enzyme elevation |
| gptkbp:synonym |
gptkb:MRTX849
|
| gptkbp:target |
KRAS G12C mutation
|
| gptkbp:UNII |
6Q1K1Q1D9F
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:Ras_GTPase
|
| gptkbp:bfsLayer |
7
|